Modafinil

  • Email
  • Help

Indications restricted following review procedure under Article 31 of Directive 2001/83/EC as amended.

The European Medicines Agency has completed a review of the safety and effectiveness of modafinil. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of modafinil-containing medicines continue to outweigh their risks but that their use should be restricted to the treatment of narcolepsy. The CHMP also recommended further changes to the product information to ensure that the medicines are used appropriately, and asked the manufacturers to put in place risk minimisation measures. 

After re-examination, the Committee confirmed these recommendations on 18 November 2010.

What is modafinil?

Modafinil is used to promote wakefulness (help people stay awake). The exact way modafinil works is not fully understood, but it most likely interacts with some chemicals in the brain called neurotransmitters such as dopamine and norepinephrine. Modafinil-containing medicines are used in patients who suffer from excessive sleepiness. Excessive sleepiness can be caused by narcolepsy, a disease that causes the person to fall asleep during the day, or it can be due to disturbed night-time sleeping patterns leading to daytime sleepiness. This can be seen in people who work a shift-pattern or in those who suffer from obstructive sleep apnoea (a condition in which pauses in breathing occur repeatedly during the night, disturbing sleep). Excessive sleepiness can also happen with no known causes (idiopathic hypersomnia).

Medicines containing modafinil were first marketed in Europe in 1992. They are available in Austria, Belgium, Cyprus, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Poland, Portugal, Slovakia, Spain, Sweden and the United Kingdom. They are available under the following invented names: Modasomil, Modiodal, Provigil and Vigil, and as generic medicines.

Why was modafinil reviewed?

In 2007, the CHMP’s Pharmacovigilance Working Party (PhVWP) reviewed the safety of modafinil-containing medicines because of concerns that the medicines were associated with serious psychiatric disorders (suicidal thoughts, mania and symptoms of psychosis such as delusion) and with skin reactions, including severe reactions such as Stevens-Johnson syndrome, a life-threatening type of allergic reaction affecting the skin and mucous membranes. This led to an update of the product information for modafinil-containing medicines across Europe to strengthen the warnings about these risks. The PhVWP also asked the companies that make modafinil-containing medicines to provide all information they had to assess if further measures were needed.

Once the PhVWP had received and started its assessment of the data, the working party had further concerns about the medicines, and consequently, on 14 May 2009, the UK medicines regulatory agency asked the CHMP to carry out a full assessment of the benefit-risk balance of modafinil-containing medicines, and to issue an opinion on whether their marketing authorisations should be maintained, varied, suspended or withdrawn across the European Union.

Which data has the CHMP reviewed?

The Committee looked at all the data from the clinical trials of modafinil in narcolepsy, obstructive sleep apnoea, shift-work sleep disorder and idiopathic hypersomnia, and at articles from the published literature. The CHMP also reviewed all the side effects reported with modafinil-containing medicines. A group of experts on clinical neurosciences was also convened to provide advice.

What are the conclusions of the CHMP?

Looking at the data from the clinical trials, the Committee noted that the effectiveness of modafinil in narcoleptic patients had been shown. However, the data from the trials in other disorders did not provide strong evidence to support the use of the product.

Looking at the safety data, the Committee noted that modafinil is strongly linked to a risk of serious, life-threatening skin reactions, and this risk appears higher in children. The Committee also noted a link between modafinil and psychiatric adverse reactions, such as suicidal thoughts, depression, psychotic episodes, and between modafinil and cardiovascular adverse reactions, such as hypertension (high blood pressure) and irregular heart beat.

Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of modafinil-containing medicines continue to outweigh their risks only in the treatment of narcolepsy. For obstructive sleep apnoea (including in patients with excessive sleepiness despite correctly using a Continuous Positive Airway Pressure machine), shift-work sleep disorder and idiopathic hypersomnia, the CHMP concluded that the data on the effectiveness were not sufficient to outweigh the risks, and that therefore the benefit-risk balance was negative. The Committee recommended that these indications be removed from the product information. In addition the Committee also recommended that modafinil-containing medicines not be used in patients with uncontrolled hypertension or irregular heart beat. The Committee also noted the increased risk of serious life-threatening skin reactions with modafinil in children and advised against its use in children.

The CHMP has also asked the companies that make modafinil-containing medicines to put in place measures to minimise the risks. These include informing healthcare professional of the changes to the product information triggered by this latest review, and putting in place studies looking at the cardiovascular and skin safety of modafinil. Because the Committee noted in its review that modafinil has often been used for conditions for which it is not indicated, the companies have also been asked to carry out further studies, including a ‘drug utilisation study’ to look at why family doctors prescribe the medicines. In addition, data on the misuse of modafinil by university students, currently being collected, will be analysed once available.

The CHMP confirmed the above conclusions after re-examining its opinion. The full changes made to the information to doctors and patients are detailed here.

What are the recommendations for prescribers and patients?
  • Doctors prescribing modafinil-containing medicines should keep in mind the change in the indication: modafinil is only indicated to treat narcolepsy.
  • Modafinil should no longer be used to treat:
    • Obstructive sleep apnoea;
    • Shift work sleep disorder;
    • Idiopathic hypersomnia.
  • Doctors should also be aware of the safety profile of modafinil-containing medicines, and they should monitor their patients appropriately.
  • Patients who are receiving modafinil-containing medicines should contact their doctors at a convenient time to check that they should continue receiving it.
  • There is no need for patients to stop treatment with modafinil immediately, but patients who wish to stop can do so at any time.
  • Patients who have any questions should speak to their doctor or pharmacist.

The European Commission issued a decision on 27 January 2011.

Name Language First published Last updated
Questions and answers on the review of medicines containing modafinil - Re-examination BG = bălgarski 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination ES = español 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination CS = čeština 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination DA = dansk 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination DE = Deutsch 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination ET = eesti keel 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination EL = elliniká 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination EN = English 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination FR = français 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination IT = italiano 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination LV = latviešu valoda 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination LT = lietuvių kalba 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination HU = magyar 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination MT = Malti 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination NL = Nederlands 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination PL = polski 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination PT = português 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination RO = română 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination SK = slovenčina 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination SL = slovenščina 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination FI = suomi 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination SV = svenska 2010-11-19 2011-04-26

Key facts

Approved nameModafinil
International non-proprietary name (INN) or common name

modafinil

Associated namesModasomil, Modiodal, Provigil, Vigil
Class
Reference numberEMEA/H/A-31/1186
TypeArticle 31 referrals

This type of referral is triggered when the interest of the Community is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

StatusEuropean Commission final decision
Opinion date18/11/2010

All documents

Name Language First published Last updated
Modafinil-H-A-31-1186: Article 31 Referral-Assessment report (English only) 2011-04-26  
Questions and answers on the review of medicines containing modafinil - Initial (English only) 2010-07-22  
Questions and answers on the review of medicines containing modafinil - Re-examination BG = bălgarski 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination ES = español 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination CS = čeština 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination DA = dansk 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination DE = Deutsch 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination ET = eesti keel 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination EL = elliniká 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination EN = English 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination FR = français 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination IT = italiano 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination LV = latviešu valoda 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination LT = lietuvių kalba 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination HU = magyar 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination MT = Malti 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination NL = Nederlands 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination PL = polski 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination PT = português 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination RO = română 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination SK = slovenčina 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination SL = slovenščina 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination FI = suomi 2010-11-19 2011-04-26
Questions and answers on the review of medicines containing modafinil - Re-examination SV = svenska 2010-11-19 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV BG = bălgarski 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV ES = español 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV CS = čeština 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV DA = dansk 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV DE = Deutsch 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV ET = eesti keel 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV EL = elliniká 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV EN = English 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV FR = français 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV IT = italiano 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV LV = latviešu valoda 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV LT = lietuvių kalba 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV HU = magyar 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV MT = Malti 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV NL = Nederlands 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV PL = polski 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV PT = português 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV RO = română 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV SK = slovenčina 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV SL = slovenščina 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV FI = suomi 2010-07-22 2011-04-26
Modafinil - Article 31 referral - Annex I, II, III, IV SV = svenska 2010-07-22 2011-04-26

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

  • Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes have been recommended by the Committee
  • Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be taken for the marketing authorisation(s) such as safety measures or extra studies

Current status:
European Commission final decision

Further information on Modafinil